*Articles from the former Asklep
ASKLEP Inc. a Japan CRO and Korea’s largest CRO DreamCIS Inc., announce the two companies have signed a Strategic Partnership Agreement to provide reciprocal clinical research services in their respective territories. Both companies provide clinical monitoring, data management, statistical analysis among other, to pharmaceutical, biotech and device manufacturers. ASKLEP & DreamCIS will jointly market and develop business particularly for Japanese Pharmaceutical companies wishing to conduct trials in Korea in line with their clinical development strategy.
This is a strategic partnership for ASKLEP having already secured a partnership in Taiwan with Qualitix Clinical Research. Adding a strong partner like DreamCIS in Korea means ASKLEP will be able to offer their pharmaceutical clients high quality clinical research expertise in the three key Asian geographies, Japan, Korea and Taiwan.
ASKLEP over the past year has been very active in establishing partnerships with CROs around the globe including, ASKA Research of North America and Harrison Clinical Research Group of Europe.
About Dream CIS
With abundant experience and know-how, DreamCIS (www.dreamcis.com) helps pharmaceutical, biotech and device manufacturers plan and manage trials from beginning to end. DreamCIS strengths are study consulting and study design, medical writing and feasibility for patient recruitment along with subsequent clinical monitoring. DreamCIS provides clinical trial services, either for an entire project or certain stages of a project, that meet client needs, in accordance with KGCP, GCP and ICH guidelines. Since the company established in 2000, DreamCIS has conducted 255 clinical trials in Phase I to IV, and over 480 projects in Pharmacovigilance and Post-Marketing Surveillance.